MacroGenics, Inc.
MGNX$149M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaRockville341 employees
Drugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Sep 15, 2026
26wMarket Overview
Stock performance and key metrics
MGNX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Teplizumab
Type 1 Diabetes Mellitus
Margetuximab
HER-2 Positive Breast Cancer
Retifanlimab
Gastric Cancer
Margetuximab 10 mg/kg
Gastric Cancer
MGD007 + MGA012
Colorectal Cancer Metastatic
vobramitamab duocarmazine 2.0 mg (Arm A)
Castration-Resistant Prostatic Cancer
lorigerlimab
Androgen-Independent Prostatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Teplizumab | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Margetuximab | Phase 3 | HER-2 Positive Breast Cancer | - | - |
Retifanlimab | Phase 3 | Gastric Cancer | - | - |
Margetuximab 10 mg/kg | Phase 2 | Gastric Cancer | - | - |
MGD007 + MGA012 | Phase 2 | Colorectal Cancer Metastatic | - | - |
vobramitamab duocarmazine 2.0 mg (Arm A) | Phase 2 | Castration-Resistant Prostatic Cancer | - | - |
lorigerlimab | Phase 2 | Androgen-Independent Prostatic Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply